Conference abstract · 28 Jul 2016
CommentaryPublished 28 Jan 2022
A Cross-country Review of HTA Decision Making: Novel Non-small Cell Lung Cancer Treatments
Subjects
Pharmaceutical SciencesSimilar by topic
Research article · 29 Dec 2017
Analytical Methods of Six FDA Approved Molecular Entities Used for the Treatment of Non-Small Cell Lung Cancer: A Concise Review
Research article · 12 May 2025
A New Approach to Treating Non-Small Cell Lung Cancer: Direct Thrombin Inhibitors Block the Disease's Spread and Spontaneous Metastasis
Article · 20 Feb 2024
Effect of Erlotinib Combined with Radiotherapy on Proliferation and Apoptosis of Human Non-Small Cell Lung Cancer Cells and its Possible Mechanism Exploration
Article · 20 Jan 2024
Efficacy Observation of Continuous Intervention in Conjunction with Bevacizumab in Managing Non-Small Cell Lung Cancer
More from this journal
The newest in Pharmacoeconomics: Open Access.
Opinion · 1 Dec 2025
Drug Repurposing: Economic Gains, Faster Pathways, Rare Diseases
Short communication · 1 Dec 2025
Preventive Drugs for Older Adults: Health and Economic Benefits
Brief report · 29 Nov 2025
Value Assessment Of High-cost Specialty Drugs
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmacoeconomics: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Patrich J. Welch”

